Leavell Investment Management Inc. Has $6.23 Million Position in Eli Lilly and Company (NYSE:LLY)

Leavell Investment Management Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,547 shares of the company's stock after acquiring an additional 1,113 shares during the quarter. Leavell Investment Management Inc.'s holdings in Eli Lilly and Company were worth $6,233,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Quotient Wealth Partners LLC grew its position in Eli Lilly and Company by 6.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,352 shares of the company's stock worth $2,768,000 after purchasing an additional 198 shares during the last quarter. Alpha Financial Partners LLC grew its position in Eli Lilly and Company by 8.1% during the 1st quarter. Alpha Financial Partners LLC now owns 493 shares of the company's stock worth $407,000 after purchasing an additional 37 shares during the last quarter. Topsail Wealth Management LLC grew its position in Eli Lilly and Company by 6.2% during the 1st quarter. Topsail Wealth Management LLC now owns 776 shares of the company's stock worth $641,000 after purchasing an additional 45 shares during the last quarter. Moloney Securities Asset Management LLC grew its position in Eli Lilly and Company by 6.0% during the 1st quarter. Moloney Securities Asset Management LLC now owns 6,877 shares of the company's stock worth $5,679,000 after purchasing an additional 388 shares during the last quarter. Finally, Banque Pictet & Cie SA grew its position in Eli Lilly and Company by 8.0% during the 1st quarter. Banque Pictet & Cie SA now owns 88,282 shares of the company's stock worth $72,913,000 after purchasing an additional 6,505 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $2.69 during mid-day trading on Friday, hitting $793.34. The stock had a trading volume of 2,851,585 shares, compared to its average volume of 3,670,273. The stock has a market capitalization of $751.88 billion, a price-to-earnings ratio of 64.55, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a 50 day simple moving average of $766.39 and a 200-day simple moving average of $799.99. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.58 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Wall Street Zen downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a report on Friday. Finally, The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.